Condition
Complication of Transplanted Liver
Total Trials
5
Recruiting
0
Active
1
Completed
3
Success Rate
75.0%-12% vs avg
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
75.0%
-11.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
75% success
Data Visualizations
Phase Distribution
1Total
P 4 (1)
Trial Status
Completed3
Terminated1
Active Not Recruiting1
Trial Success Rate
75.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT02784080Active Not RecruitingPrimary
Donor Specific HLA Alloantibodies in Liver Transplantation
NCT02223468Completed
Human Microbiota and Liver Transplant
NCT02624349Phase 4Completed
Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients
NCT00867243TerminatedPrimary
Prediction of Hepatitis C Recurrence in Liver Transplant Recipients
NCT00857844CompletedPrimary
Genetic Predisposition-Chronic Nephrotoxicity From CI-Liver Transplant Recipients-Potential Correlation-Urinary Biomarkers
Showing all 5 trials